uniQure N.V. is the subject of a securities class action lawsuit stemming from allegations that the company failed to disclose material information regarding its AMT-130 drug candidate. According to court documents, the biotechnology firm had previously indicated a high probability of FDA accelerated approval for the therapy. However, on November 3, 2025, uniQure disclosed that the FDA had determined the Phase I/II trial data was insufficient to support a Biologics License Application submission, contradicting earlier representations to investors.
The disclosure triggered a significant market reaction, with uniQure's stock price declining approximately 49 percent, falling from $67.69 to $34.29 in the trading session following the announcement. Shareholders who sustained losses exceeding $100,000 during the class period are eligible to participate in the litigation by submitting lead plaintiff applications.
Investors meeting the loss threshold must file their applications by April 13, 2026, to be considered as potential lead plaintiffs in the case. Those with questions regarding their eligibility or the claims process are encouraged to seek guidance from qualified legal counsel specializing in securities litigation.